Compare MWG & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWG | PPBT |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 4.4M |
| IPO Year | 2022 | 2014 |
| Metric | MWG | PPBT |
|---|---|---|
| Price | $1.89 | $4.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 21.6K | 11.3K |
| Earning Date | 06-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.41 |
| 52 Week High | $2.49 | $5.18 |
| Indicator | MWG | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 52.87 |
| Support Level | $1.79 | $3.70 |
| Resistance Level | $2.20 | $4.39 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 21.44 | 41.83 |
Multi Ways Holdings Ltd is a supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region. The wide variety of new and used heavy construction equipment for sale and rental by customers range from: earth-moving equipment such as bulldozers, off-terrain dump trucks, excavators and wheel loaders; material-handling equipment such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts and telescopic handlers; road-building equipment such as motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers and mini excavators; and generators and compressors, such as air compressors, generators, lighting towers and welding machines.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.